Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: PNB-0408
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptidomimetic
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
HGF/MET involvement remains a preclinical research hypothesis: the retracted 2014 paper is not affirmative support, while separate antagonist/cell work warrants further investigation.
Evidence and critical reading
Reported scientific and empirical uses
Cognition and neurology
Described for cognition and synaptogenesis; superiority-to-BDNF claims are extrapolations.
Human evidence
No human clinical benefit established here.
Preclinical evidence
Dihexa is an experimental peptidomimetic studied in laboratory and animal models. A key 2014 HGF/c-Met mechanism paper was retracted in 2025; the separate 2013 discovery study carries a 2021 notice of concern. Other animal studies report model-dependent findings, including benefits in some memory tasks and a negative result in a rat model of Huntington-like disease. Additional preclinical work supports investigation of HGF/MET involvement, but the sources reviewed do not establish cognitive benefit, safety, or a validated dosing regimen in people. Laboratory potency comparisons must not be presented as proof of clinical superiority over BDNF. Scientific/expert review pending.
Critical reading and limitations
Sun et al. (2021; PMID34827486) reported positive APP/PS1 mouse findings, but methods describe both intragastric and intraperitoneal routes and lack an inhibitor-only control; route reporting is unresolved. Wells et al. (2024; PMID38489193) reported a negative Huntington-like toxin rat-model result; only abstract/bibliography were reviewed. Martino et al. (first online November 20, 2025; PMID42825082) reported working-memory benefits after repeated mild TBI with intracerebroventricular rat administration. Antagonist and cell assays support further HGF/MET investigation, not human or oral-product validation. The 2025 retraction notice for the 2014 paper identifies data falsification/fabrication in specified figures/erratum after a university investigation. This does not retract all Dihexa research or conclusively disprove HGF/MET involvement. No raw-data reanalysis or full-supplement appraisal is claimed.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
10–40 mg · Total daily amount
- Frequency
- Daily
- Duration
- Not stated on selected page.
- Route
- Oral
- Context
- Handbook cognitive promotion; review mechanism retraction R37.
- Presentation
- 10/20-mg capsules on previous page.
- Interpretation
- Regimen attributed to handbook, without clinical validation for this use; not a recommendation.
manual01 · Page 43 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human toxicity and interactions remain unknown; growth signaling concern is a hypothesis, not a measured cancer rate.
Clinical efficacy and sufficient human safety were not verified; handbook dosing does not resolve the gap.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Dihexa · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REVIEW02-PMID25187433
Benoist et al. — 2014 HGF/c-Met mechanism study (retracted April 2025; historical source only)
- REVIEW02-PMID40312093
Benoist et al. — April 2025 retraction notice for the 2014 mechanism paper
- REVIEW02-PMID23055539
McCoy et al. — 2013 Dihexa discovery study (separate 2021 notice of concern)
- REVIEW02-PMID34551989
McCoy et al. — 2021 notice of concern for the separate 2013 discovery study
- REVIEW02-PMID34827486
- REVIEW02-PMID38489193
Wells et al. — 2024 negative Huntington-like toxin rat-model study
- REVIEW02-PMID42825082
Martino et al. — repeated mild TBI rat working-memory research, first online November 20, 2025
- PMID40312093
Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW.
October 16, 2026
- R06
- R37
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026